Prevention and Screening of CRC

Publication
Article
Special ReportsGastrointestinal Cancers (Issue 5)
Volume 4
Issue 2

Nadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center (ICPC), Tel Aviv Sourasky Medical Center, discusses prevention and screening of colorectal cancer (CRC).

Articles in this issue
Proteomic Study in CRC of Paired Tumor Versus Nontumor Tissue May Identify New Biomarkers
Proteomic Study in CRC of Paired Tumor Versus Nontumor Tissue May Identify New Biomarkers
Managing the Elderly Patient With Unresectable HCC: Q and A With Pierre M. Gholam, MD, AGAF
Managing the Elderly Patient With Unresectable HCC: Q and A With Pierre M. Gholam, MD, AGAF
Prevention and Screening of CRC
Prevention and Screening of CRC
Survival Differences in KRAS/BRAF Mutations in mCRC
Survival Differences in KRAS/BRAF Mutations in mCRC
Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials
Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials
New Agents Show Potency for Patients with HCC
New Agents Show Potency for Patients with HCC
Success of Regorafenib Confirmed in Patients With mCRC
Success of Regorafenib Confirmed in Patients With mCRC
Agents Under Examination Demonstrate Success in Gastric Cancer
Agents Under Examination Demonstrate Success in Gastric Cancer

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Jacobson Discusses Second and Third-Line Options for DLBCL

Jacobson Discusses Second and Third-Line Options for DLBCL

Targeted Oncology Staff
April 19th 2025
Article

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

Analysis Illuminates CAR T-Cell Optimization for CLL

Analysis Illuminates CAR T-Cell Optimization for CLL

Morgan Bayer
April 17th 2025
Article

Fewer prior therapies with liso-cel in chronic lymphocytic leukemia showed improved overall response rate in TRANSCEND-CLL-004 analysis.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

Immunotherapy Inches Forward in Head and Neck Cancer Trials

Immunotherapy Inches Forward in Head and Neck Cancer Trials

Tony Berberabe, MPH
April 16th 2025
Article

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly delineated, even in phase 3 trials.

Read More

AI May Replace the Front Desk in Health Care

AI May Replace the Front Desk in Health Care

Jock Putney
April 15th 2025
Article

AI is no longer in the realm of speculative science fiction—it’s here, and it’s moving fast.

Read More